Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Novavax Inc (NVAX) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Novavax Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.66, while Novavax Inc trades at $8.22 (market cap $1.39B). Which is the better fit depends on your goals.

FEPINVAX
Sector
Income / Options OverlayHealth
52-Week High
$49.54$11.19
52-Week Low
$38.13$6.22
Market Cap
$1.39B
Enterprise Value
$890.94M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.76, down 1.6% today, with a bearish technical signal from moving averages. The ETF generates high income through weekly covered call distributions, recently transitioning to weekly payouts. Recent dividends show consistent payments around $0.20-$0.22 per share, with one larger $0.90 distribution in April 2026. The concentrated portfolio of AI and mega-cap tech names provides QQQ-like exposure but with capped upside from call writing.

The outlook remains cautious due to NAV erosion risks from the covered call strategy limiting participation in rallies. While the 25% yield attracts income seekers, total returns have lagged broader tech indices. Key risks include high portfolio concentration and market volatility impacting premium income generation. Analyst views are mixed, balancing high yield against structural limitations.

Novavax Inc

Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.

The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX